The Trump administration’s historic marijuana rescheduling move is good news for the cannabis industry’s tax fight. But 280E relief won’t be broad.
This is a contributed guest column. To be considered as an MJBizDaily guest columnist, please submit your request here.)
The legal marijuana industry’s situation changed significantly on Thursday when the U.S. Justice Department finally rescheduled cannabis – but only some cannabis.
The Trump Justice Department placed U.S. Food and Drug Administration-approved drug products containing cannabis and marijuana produced by operators with a state-issued medical license in Schedule 3 of the Controlled Substances Act.
Notably, this move left all other marijuana, including unlicensed bulk marijuana and state-legal adult-use commerce, in Schedule 1.
The upshot is not “cannabis is moved to Schedule 3” in the broad sense. This is a medical-only action with immediate and uneven consequences across the industry.
For those hoping for rescheduling and tax relief from Section 280E, including those intently watching a key Internal Revenue Service challenge in tax court, this development isn’t likely to help.
Here’s why those hopes are likely headed for disappointment.
What cannabis operators still need to know after marijuana rescheduling
Both the legal and practical endgames are far from settled. The DOJ’s order itself anticipates severability (meaning certain parts of it may be deemed litigation. And it draws a bright line between state medical licensees, who the order states should no longer be subject to Section 280E, and the much larger adult-use market, which the order explicitly leaves in Schedule 1.
That split structure all but guarantees immediate challenges:
- From opponents who will attack the use of a particular section of federal law to implement a partial, medical-only rescheduling regime
- From cannabis industry stakeholders, who will argue that a substance cannot be treated as Schedule 3 for some channels while remaining Schedule 1 for others.
But questions of legal strategy should not obscure the separate questions:
- What cannabis taxpayers can and cannot do today based on the government’s current position?
- What exposure exists for positions already taken on past-year federal tax returns — particularly for operators whose core business remains Schedule 1 trafficking under federal law?
Why Trump marijuana rescheduling doesn’t solve the 280E puzzle
The cannabis industry’s severe tax problems are well known. Internal Revenue Code Section 280E disallows deductions for ordinary business expenses incurred in trafficking Schedule 2 or 3 controlled substances, while still permitting cost of goods sold. Many cannabis taxpayers are not able to pay the resulting tax.\
Read the full article at
